Status:
COMPLETED
Clinical Evaluation of the Next Generation Phaco System
Lead Sponsor:
Johnson & Johnson Surgical Vision, Inc.
Conditions:
Cataract
Eligibility:
All Genders
22+ years
Phase:
NA
Brief Summary
This study is a prospective, open-label clinical study of the VERITAS Vision System. The study will be conducted at up to three sites, with minimum 55 eyes and up to 150 eyes to be treated. The inves...
Eligibility Criteria
Inclusion
- Minimum 22 years of age.
- Cataracts for which cataract extraction and posterior chamber IOL implantation have been planned.
- Availability, willingness, ability and sufficient cognitive awareness to comply with study requirements, examination procedures, and visits.
- Be willing to provide informed consent and authorization to disclose protected health information or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical procedures in the governing countries.
Exclusion
- Expected surgical difficulties at the time of cataract extraction, which may increase the potential for complications (e.g., persistent bleeding, significant iris damage, uncontrolled intraocular pressure change, or significant vitreous prolapse or loss).
- Subjects with only one good eye (e.g. amblyopic condition etc.).
- Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration, including pseudoexfoliation, trauma, or posterior capsule defects.
- History or current use of alpha-1 antagonist medication (e.g., Flomax).
- Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study or for which cataract surgery is contraindicated.
- Pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils).
- Is pregnant, or is breast feeding, or intend to become pregnant during the study.
- Concurrent participation or expected participation in an interventional (i.e., surgical or pharmaceutical interventional) clinical trial within 14 days prior to study screening.
Key Trial Info
Start Date :
September 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2021
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT04332640
Start Date
September 28 2020
End Date
May 1 2021
Last Update
June 15 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
ACE Eyecare, Inc
Bakersfield, California, United States, 93301
2
Grupo Oftalmo & Plastico, Centro de Oftalmologia y Cirugia Plastica
El Escalón, San Salvador Department, El Salvador